Despite recent discoveries indicating atypical PCSK9 expression in various cancers [43], such as gastric cancer [44] and breast cancer [45], inhibiting PCSK9 has been documented to elevate cell surface levels of major histocompatibility complex class I and impede tumor growth in cancer cells [46]. The gene discussed is PCSK9; the disease is breast carcinoma.